Alexandra Hockla
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Alexandra Hockla has a total of 19 co-authors. Here are the top co-authors by number of shared publications:
- Evette S. Radisky
Department of Cancer Biology, Mayo Clinic, Jacksonville, Florida, USA
6 shared publications - John A. Copland
Department of Cancer Biology, Mayo Clinic, Jacksonville, Florida
5 shared publications - Derek C. Radisky
Department of Cancer Biology, Mayo Clinic, Jacksonville, USA
4 shared publications - Erin Miller
New York University Long Island School of Medicine
4 shared publications Moh'D A. Salameh
4 shared publications- Matt Coban
Department of Cancer Biology, Mayo Clinic, Jacksonville, FL 32224, USA
2 shared publications
Latest Publications
- Open Access
- 4 July 2025
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 11 (27) , eadu9129
Discovery of an autoinhibited conformation in mesotrypsin reveals a strategy for selective serine protease inhibition
Selective inhibition of the more than 100 S1 family serine proteases is a long-standing challenge due to their active site similarity. Mesotrypsin, implicated in cancer progression, exemplifies these difficulties; no current inhibitors achieve selectivity over other human trypsins. We found an unexpected autoinhibited conformation of mesotrypsin via x-ray crystallography, revealing a cryptic pocket adjacent to the active site. Using high-throughput virtual screening targeting this cryptic pocket, we identified a conformationally selective small-molecule inhibitor that stabilizes the inactive state of mesotrypsin. This inhibitor demonstrates selectivity for mesotrypsin over other trypsins. Our findings challenge the accepted view of digestive trypsins as constitutively active enzymes lacking potential for allosteric regulation. Furthermore, analyses of other structures suggest that dynamic sampling of closed states with analogous allosteric cryptic pockets appears widespread among S1 serine proteases. These observations point to a potentially generalizable strategy to achieve selective inhibition, offering broad implications for drug development targeting serine proteases in cancer and other diseases.
- 4 July 2025
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 11 (27) , eadu9129
Open AccessDiscovery of an autoinhibited conformation in mesotrypsin reveals a strategy for selective serine protease inhibition
Selective inhibition of the more than 100 S1 family serine proteases is a long-standing challenge due to their active site similarity. Mesotrypsin, implicated in cancer progression, exemplifies these difficulties; no current inhibitors achieve selectivity over other human trypsins. We found an unexpected autoinhibited conformation of mesotrypsin via x-ray crystallography, revealing a cryptic pocket adjacent to the active site. Using high-throughput virtual screening targeting this cryptic pocket, we identified a conformationally selective small-molecule inhibitor that stabilizes the inactive state of mesotrypsin. This inhibitor demonstrates selectivity for mesotrypsin over other trypsins. Our findings challenge the accepted view of digestive trypsins as constitutively active enzymes lacking potential for allosteric regulation. Furthermore, analyses of other structures suggest that dynamic sampling of closed states with analogous allosteric cryptic pockets appears widespread among S1 serine proteases. These observations point to a potentially generalizable strategy to achieve selective inhibition, offering broad implications for drug development targeting serine proteases in cancer and other diseases.
- Open Access
Improving Circulation Half-Life of Therapeutic Candidate N-TIMP2 by Unfolded Peptide Extension
Matrix Metalloproteinases (MMPs) are drivers of many diseases including cancer and are established targets for drug development. Tissue inhibitors of metalloproteinases (TIMPs) are human proteins that inhibit MMPs and are being pursued for the development of anti-MMP therapeutics. TIMPs possess many attractive properties of a drug candidate, such as complete MMP inhibition, low toxicity and immunogenicity, high tissue permeability and others. A major challenge with TIMPs, however, is their formulation and delivery, as these proteins are quickly cleared from the bloodstream due to their small size. In this study, we explore a new method for plasma half-life extension for the N-terminal domain of TIMP2 (N-TIMP2) through appending it with a long intrinsically unfolded tail containing a random combination of Pro, Ala, and Thr (PATylation). We design, produce and explore two PATylated N-TIMP2 constructs with a tail length of 100- and 200-amino acids (N-TIMP2-PAT 100 and N-TIMP2-PAT 200 , respectively). We demonstrate that both PATylated N-TIMP2 constructs possess apparent higher molecular weights compared to the wild-type protein and retain high inhibitory activity against MMP-9. Furthermore, when injected into mice, N-TIMP2-PAT 200 exhibited a significant increase in plasma half-life compared to the non-PATylated variant, enhancing the therapeutic potential of the protein. Thus, we establish that PATylation could be successfully applied to TIMP-based therapeutics and offers distinct advantages as an approach for half-life extension, such as fully genetic encoding of the gene construct, mono-dispersion, and biodegradability. Furthermore, PATylation could be easily applied to N-TIMP2 variants engineered to possess high affinity and selectivity toward individual MMP family members, thus creating attractive candidates for drug development against MMP-related diseases.
Open AccessImproving Circulation Half-Life of Therapeutic Candidate N-TIMP2 by Unfolded Peptide Extension
Matrix Metalloproteinases (MMPs) are drivers of many diseases including cancer and are established targets for drug development. Tissue inhibitors of metalloproteinases (TIMPs) are human proteins that inhibit MMPs and are being pursued for the development of anti-MMP therapeutics. TIMPs possess many attractive properties of a drug candidate, such as complete MMP inhibition, low toxicity and immunogenicity, high tissue permeability and others. A major challenge with TIMPs, however, is their formulation and delivery, as these proteins are quickly cleared from the bloodstream due to their small size. In this study, we explore a new method for plasma half-life extension for the N-terminal domain of TIMP2 (N-TIMP2) through appending it with a long intrinsically unfolded tail containing a random combination of Pro, Ala, and Thr (PATylation). We design, produce and explore two PATylated N-TIMP2 constructs with a tail length of 100- and 200-amino acids (N-TIMP2-PAT 100 and N-TIMP2-PAT 200 , respectively). We demonstrate that both PATylated N-TIMP2 constructs possess apparent higher molecular weights compared to the wild-type protein and retain high inhibitory activity against MMP-9. Furthermore, when injected into mice, N-TIMP2-PAT 200 exhibited a significant increase in plasma half-life compared to the non-PATylated variant, enhancing the therapeutic potential of the protein. Thus, we establish that PATylation could be successfully applied to TIMP-based therapeutics and offers distinct advantages as an approach for half-life extension, such as fully genetic encoding of the gene construct, mono-dispersion, and biodegradability. Furthermore, PATylation could be easily applied to N-TIMP2 variants engineered to possess high affinity and selectivity toward individual MMP family members, thus creating attractive candidates for drug development against MMP-related diseases.
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 1 from PRSS3/Mesotrypsin Is a Therapeutic Target for Metastatic Prostate Cancer
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 1 from PRSS3/Mesotrypsin Is a Therapeutic Target for Metastatic Prostate Cancer
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 2 from PRSS3/Mesotrypsin Is a Therapeutic Target for Metastatic Prostate Cancer
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 2 from PRSS3/Mesotrypsin Is a Therapeutic Target for Metastatic Prostate Cancer
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Figure Legend from PRSS3/Mesotrypsin Is a Therapeutic Target for Metastatic Prostate Cancer
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure Legend from PRSS3/Mesotrypsin Is a Therapeutic Target for Metastatic Prostate Cancer